KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making. (Q54440829)
Jump to navigation
Jump to search
scientific article published in February 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making. |
scientific article published in February 2015 |
Statements
KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making (English)
Alma D Campos-Parra
Carlos Zuloaga
María Eugenia Vazquez Manríquez
Alejandro Avilés
Jose Borbolla-Escoboza
Andrés Cardona
Abelardo Meneses
1 February 2015